<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573169</url>
  </required_header>
  <id_info>
    <org_study_id>PREVENTIHS</org_study_id>
    <nct_id>NCT01573169</nct_id>
  </id_info>
  <brief_title>PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients</brief_title>
  <acronym>PREVENTIHS</acronym>
  <official_title>PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cerebral hemorrhage (ICH) have a high risk of venous thromboembolism.
      Intermittent pneumatic compression combined with elastic stockings have been shown to be
      superior to elastic stockings alone in reducing the rate of asymptomatic deep vein thrombosis
      after ICH in a randomized trial (4.7% vs. 15.9%). Graduated compression stockings alone are
      ineffective in preventing deep vein thrombosis in patients with ischemic or hemorrhagic
      stroke. Less clear is the role of anticoagulation in the prevention of venous thromboembolism
      in patients with ICH because the use of anticoagulants may cause an enlargement of the
      hematoma. In a multicenter, randomized trial, the investigators will assess the efficacy and
      safety of enoxaparin in the prevention of venous thromboembolism in patients with spontaneous
      intracerebral hemorrhage. Enoxaparin (40 mg once daily) or standard therapy (graduated
      compression stockings and/or intermittent pneumatic compression and/or early mobilization)
      will be given subcutaneously for not less than 10 days beginning after 72 hours from stroke
      onset.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic and asymptomatic venous thromboembolism</measure>
    <time_frame>10 days</time_frame>
    <description>Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleedings</measure>
    <time_frame>90 days</time_frame>
    <description>symptomatic and asymptomatic intra and extracranial bleedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>90 days</time_frame>
    <description>mortality of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disability</measure>
    <time_frame>90 days</time_frame>
    <description>modified Rankin Scale (mRS) equal to and greater than 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Hemorrhagic Stroke</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>low weight molecular heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoxaparin 0.4 ml subcutaneous per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
    <arm_group_label>low weight molecular heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization</intervention_name>
    <description>placebo standard therapy</description>
    <arm_group_label>standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intracranial spontaneous hemorrhage on brain CT scan

          -  Intracranial hemorrhage during treatment with oral anticoagulants

          -  Bedridden patients (item 6 of NIHSS: motor leg points 3 or 4 or severe ataxia for
             cerebellar hemorrhage).

        Exclusion Criteria:

          -  cerebral hemorrhage due to intracranial vascular malformation

          -  rebleeding on CT scan after 72 hours from stroke (before randomization)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maurizio Paciaroni, MD</last_name>
    <phone>0039 (0)75 5782765</phone>
    <email>maurizio.paciaroni@unipg.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stroke Unit</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Paciaroni</last_name>
    </contact>
    <contact_backup>
      <email>maurizio.paciaroni@unipg.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost. 2011 May;9(5):893-8. doi: 10.1111/j.1538-7836.2011.04241.x.</citation>
    <PMID>21324058</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Maurizio Paciaroni</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemorrhagic stroke</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

